Influenza Vaccines: What Does the mRNA Platform Have to Offer?
Are you up to date about current developments in influenza vaccines with the messenger RNA (mRNA) platform?
Reaching for New Heights: Breaking Down Influenza Trends and Prevention Efforts
Did you know that in female children, influenza pneumonia is the second most common cause of death?
Prevention of long COVID: progress and challenges
Long COVID—the umbrella term that encompasses the post-acute and long-term sequelae of SARS-CoV-2 infection—can be profoundly disabling and might affect people for a lifetime.
COVID-19 evolving variants and how to stay safe
Why are we seeing a rising number of COVID-19 cases in some parts of the world? How is the SARS CoV 2 virus evolving? What do Governments and the public need to do to live with COVID-19 safely? Dr Maria Van Kerkhove explains in WHO's Science in 5.
Algorithm for Optimised mRNA Design Improves Stability and Immunogenicity
mRNA vaccines are being used to contain COVID-19, but still suffer from the critical limitation of mRNA instability and degradation, which is a major obstacle in the storage, distribution, and efficacy of the vaccine products.
Progress Report: Reducing the Burden of RSV across the Lifespan
The National Foundation for Infectious Diseases (NFID) supports RSV education by engaging key audiences, sharing firsthand experiences of RSV among all age groups, and providing resources to help raise awareness of the burden of disease.
ECDC on Air podcast: The solidarity of Vaccination
European Immunization Week is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
ReSViNET's RSV Dashboard is 𝐋𝐈𝐕𝐄!
ReSViNET Foundation is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.
Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study
Early-life severe RSV infection has been associated with the onset of childhood wheezing illnesses. However, the relationship between RSV infection during infancy and the development of childhood asthma is unclear.
Association of COVID-19 Infection With Incident Diabetes
SARS-CoV-2 infection may lead to acute and chronic sequelae. Emerging evidence suggests a higher risk of diabetes after infection, but population-based evidence is still sparse.